I Don't Trust CVS Health's Stock: Here's When I Get Out

I have no patience moving forward with a large firm standing on a sloppy book, trying to digest an acquisition it needs to make, but can only questionably afford.

Electronic Arts: Let's Check for Technical Clues Amid Takeover Reports

Sometimes where there is smoke there is fire and other times not.

Biotech M&A Activity Expected to Pick Up

Here are few names that would make logical acquisition targets for larger players.

This Under-the-Radar Fund Is Giving the SPY a Run for Its Money

The Invesco S&P Spin-Off exchange-traded fund is holding its own against the SPDR S&P 500 ETF Trust. Can it keep it up?

Activision's Microsoft Deal Discount Offers a 'Call of Duty' to Investors

Berkshire Hathaway's involvement and MoffettNathan's case are enough to consider buying in.

How a Buyout Gone Bad Can Make for a Better Buy

After a failed bid from the Franchise Group, the lack of a near-term buyout made Kohl's a good play for investors. Let's see how.

Elon Musk vs Twitter: Get Ready for Months of Legal Wrangling

Musk's focus on the prevalence of spambot accounts really elucidated why TWTR is not a viable business.

Why More Cloud Software M&A Might Soon Be On the Way

Many fast-growing cloud software firms are now far from expensive, and both their business models and IT spending trends make them appealing targets.

When It Comes to Twitter, I'd Rather Trade Tesla

Of course, as Elon Musk is a finite resource, Twitter's loss is Tesla's gain.

Seagen Is Being Hotly Pursued By Merck: Here's the Trade

SGEN is a biotech with leadership precisely where big pharma wants to go.